Companies › Insud Pharma
3 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 4, 1 Phase 1; Infectious disease, Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Drospirenone (LF111) Mineralocorticoid receptor antagonist; Progesterone receptor agonist | NR3C2, PGR | Phase 4 | Change in Bone Mineral Density; Contraception | Dec 2027 |
| Albendazole-Ivermectin fixed dose combination (FDC) Dual antihelmintic fixed dose combination for soil-transmitted helminth treatment | – | Phase 3 | Soil-Transmitted Helminths | Feb 2027 |
| Benznidazole Antiparasitic agent for Trypanosoma cruzi infection | – | Phase 3 | Chagas Disease | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06345560 | Drospirenone (LF111) | Phase 1 | Contraception | Metabolic and endocrine | Jul 2026 |
| NCT06282315 | Albendazole-Ivermectin fixed dose combination (FDC) | Phase 3 | Soil-Transmitted Helminths | Infectious disease | Feb 2027 |
| NCT04024163 | Benznidazole | Phase 3 | Chagas Disease | Infectious disease | Aug 2027 |
| NCT05303636 | Drospirenone (LF111) | Phase 4 | Change in Bone Mineral Density | Metabolic and endocrine | Dec 2027 |
| NCT05303636 | Drospirenone (LF111) | Phase 4 | Change in Bone Mineral Density | Metabolic and endocrine | Dec 2027 |
Bayer Santhera Pharmaceuticals Calla Lily Clinical Care Changchun GeneScience Pharmaceutical
Labo'Life Alimera Sciences Laboratorio Farmaceutico SIT srl Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Jiangxi Qingfeng Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.